Skip to main content Back to Top
Advertisement

2/13/2024

Lenalidomide Capsules

Products Affected - Description

    • Lenalidomide oral capsule, Alvogen, 10 mg, bottle, 100 count, NDC 47811-0485-01
    • Lenalidomide oral capsule, Alvogen, 15 mg, bottle, 100 count, NDC 47811-0486-01
    • Lenalidomide oral capsule, Alvogen, 20 mg, bottle, 21 count, NDC 47811-0487-77
    • Lenalidomide oral capsule, Alvogen, 25 mg, bottle, 100 count, NDC 47811-0488-01
    • Lenalidomide oral capsule, Alvogen, 5 mg, bottle, 100 count, NDC 47811-0484-01
    • Lenalidomide oral capsule, Apotex, 10 mg, bottle, 28 count, NDC 60505-4534-02
    • Lenalidomide oral capsule, Apotex, 15 mg, bottle, 21 count, NDC 60505-4535-02
    • Lenalidomide oral capsule, Apotex, 2.5 mg, bottle, 28 count, NDC 60505-4532-02
    • Lenalidomide oral capsule, Apotex, 20 mg, bottle, 21 count, NDC 60505-4536-02
    • Lenalidomide oral capsule, Apotex, 25 mg, bottle, 21 count, NDC 60505-4537-02
    • Lenalidomide oral capsule, Apotex, 5 mg, bottle, 28 count, NDC 60505-4533-02
    • Lenalidomide oral capsule, Camber, 10 mg, bottle, 28 count, NDC 31722-0259-28
    • Lenalidomide oral capsule, Camber, 15 mg, bottle, 21 count, NDC 31722-0260-21
    • Lenalidomide oral capsule, Camber, 2.5 mg, bottle, 28 count, NDC 31722-0257-28
    • Lenalidomide oral capsule, Camber, 20 mg, bottle, 21 count, NDC 31722-0261-21
    • Lenalidomide oral capsule, Camber, 25 mg, bottle, 21 count, NDC 31722-0262-21
    • Lenalidomide oral capsule, Camber, 5 mg, bottle, 28 count, NDC 31722-0258-28
    • Lenalidomide oral capsule, Sun Pharma, 10 mg, bottle, 28 count, NDC 63304-0043-27
    • Lenalidomide oral capsule, Sun Pharma, 15 mg, bottle, 21 count, NDC 63304-0044-22
    • Lenalidomide oral capsule, Sun Pharma, 2.5 mg, bottle, 28 count, NDC 63304-0041-27
    • Lenalidomide oral capsule, Sun Pharma, 20 mg, bottle, 21 count, NDC 63304-0045-22
    • Lenalidomide oral capsule, Sun Pharma, 25 mg, bottle, 21 count, NDC 63304-0046-22
    • Lenalidomide oral capsule, Sun Pharma, 5 mg, bottle, 28 count, NDC 63304-0042-27
    • Lenalidomide oral capsule, Teva, 10 mg, bottle, 28 count, NDC 00480-1243-28
    • Lenalidomide oral capsule, Teva, 15 mg, bottle, 21 count, NDC 00480-1244-21
    • Lenalidomide oral capsule, Teva, 2.5 mg, bottle, 28 count, NDC 00480-1241-28
    • Lenalidomide oral capsule, Teva, 20 mg, bottle, 21 count, NDC 00480-1245-21
    • Lenalidomide oral capsule, Teva, 25 mg, bottle, 21 count, NDC 00480-1246-21
    • Lenalidomide oral capsule, Teva, 5 mg, bottle, 28 count, NDC 00480-1242-28

Reason for the Shortage

    • Generic lenalidomide capsules have volume restrictions as part of the patent settlements between generic companies and Celgene (Bristol Myers Squibb). The volume restrictions are expected to be in effect until January 31, 2026.
    • Alvogen did not provide a reason for the shortage.
    • Apotex did not provide a reason for the shortage.
    • Bristol Myers Squibb has Revlimid available.
    • Camber has lenalidomide capsules in short supply because the company has a license to manufacture and sell limited quantities of lenalidomide capsules.
    • Cipla has lenalidomide capsules available.
    • Dr. Reddy's was not available to provide information.
    • Mylan has lenalidomide capsules available.
    • Sun has lenalidomide capsules in short supply because the company has a license to manufacture and sell limited quantities of lenalidomide capsules.
    • Teva has lenalidomide capsules in short supply because the company has a license to manufacture and sell limited quantities of lenalidomide capsules.

Available Products

    • Revlimid oral capsule, Bristol-Myers Squibb, 10 mg, bottle, 28 count, NDC 59572-0410-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 10 mg, bottle, 100 count, NDC 59572-0410-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 15 mg, bottle, 21 count, NDC 59572-0415-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 15 mg, bottle, 100 count, NDC 59572-0415-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 2.5 mg, bottle, 28 count, NDC 59572-0402-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 2.5 mg, bottle, 100 count, NDC 59572-0402-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 20 mg, bottle, 21 count, NDC 59572-0420-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 20 mg, bottle, 100 count, NDC 59572-0420-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 25 mg, bottle, 21 count, NDC 59572-0425-21
    • Revlimid oral capsule, Bristol-Myers Squibb, 25 mg, bottle, 100 count, NDC 59572-0425-00
    • Revlimid oral capsule, Bristol-Myers Squibb, 5 mg, bottle, 28 count, NDC 59572-0405-28
    • Revlimid oral capsule, Bristol-Myers Squibb, 5 mg, bottle, 100 count, NDC 59572-0405-00
    • Lenalidomide oral capsule, Alvogen, 10 mg, bottle, 28 count, NDC 47811-0485-28
    • Lenalidomide oral capsule, Alvogen, 15 mg, bottle, 21 count, NDC 47811-0486-77
    • Lenalidomide oral capsule, Alvogen, 2.5 mg, bottle, 28 count, NDC 47811-0483-28
    • Lenalidomide oral capsule, Alvogen, 25 mg, bottle, 21 count, NDC 47811-0488-77
    • Lenalidomide oral capsule, Alvogen, 5 mg, bottle, 28 count, NDC 47811-0484-28
    • Lenalidomide oral capsule, Cipla USA, 10 mg, bottle, 28 count, NDC 69097-0382-73
    • Lenalidomide oral capsule, Cipla USA, 15 mg, bottle, 21 count, NDC 69097-0383-81
    • Lenalidomide oral capsule, Cipla USA, 2.5 mg, bottle, 28 count, NDC 69097-0604-73
    • Lenalidomide oral capsule, Cipla USA, 20 mg, bottle, 21 count, NDC 69097-0384-81
    • Lenalidomide oral capsule, Cipla USA, 25 mg, bottle, 21 count, NDC 69097-0385-81
    • Lenalidomide oral capsule, Cipla USA, 5 mg, bottle, 28 count, NDC 69097-0381-73
    • Lenalidomide oral capsule, Mylan (Viatris), 10 mg, bottle, 28 count, NDC 00378-1937-28
    • Lenalidomide oral capsule, Mylan (Viatris), 10 mg, bottle, 100 count, NDC 00378-1937-01
    • Lenalidomide oral capsule, Mylan (Viatris), 15 mg, bottle, 21 count, NDC 00378-1941-21
    • Lenalidomide oral capsule, Mylan (Viatris), 15 mg, bottle, 100 count, NDC 00378-1941-01
    • Lenalidomide oral capsule, Mylan (Viatris), 2.5 mg, bottle, 28 count, NDC 00378-1935-28
    • Lenalidomide oral capsule, Mylan (Viatris), 2.5 mg, bottle, 100 count, NDC 00378-1935-01
    • Lenalidomide oral capsule, Mylan (Viatris), 20 mg, bottle, 21 count, NDC 00378-1942-21
    • Lenalidomide oral capsule, Mylan (Viatris), 20 mg, bottle, 100 count, NDC 00378-1942-01
    • Lenalidomide oral capsule, Mylan (Viatris), 25 mg, bottle, 21 count, NDC 00378-1940-21
    • Lenalidomide oral capsule, Mylan (Viatris), 25 mg, bottle, 100 count, NDC 00378-1940-01
    • Lenalidomide oral capsule, Mylan (Viatris), 5 mg, bottle, 28 count, NDC 00378-1936-28
    • Lenalidomide oral capsule, Mylan (Viatris), 5 mg, bottle, 100 count, NDC 00378-1936-01

Estimated Resupply Dates

    • Alvogen has 20 mg capsules in 21 count bottles and all 100 count bottles on back order and the company cannot estimate a release date.
    • Apotex has lenalidomide capsules on back order and the company cannot estimate a release date.
    • Camber has limited supply of all presentations.
    • Sun Pharma has lenalidomide capsules on back order and the company estimates additional product will be available in mid-March 2024.
    • Teva has lenalidomide capsules on back order and the company estimates additional product will be available in early-March 2024. Check with your wholesaler as they may have product.

Updated

Updated February 13, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 11, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT